全文获取类型
收费全文 | 8122篇 |
免费 | 698篇 |
国内免费 | 213篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 90篇 |
妇产科学 | 84篇 |
基础医学 | 746篇 |
口腔科学 | 153篇 |
临床医学 | 883篇 |
内科学 | 832篇 |
皮肤病学 | 93篇 |
神经病学 | 371篇 |
特种医学 | 231篇 |
外科学 | 599篇 |
综合类 | 1270篇 |
一般理论 | 3篇 |
预防医学 | 1981篇 |
眼科学 | 80篇 |
药学 | 769篇 |
7篇 | |
中国医学 | 440篇 |
肿瘤学 | 359篇 |
出版年
2023年 | 131篇 |
2022年 | 213篇 |
2021年 | 301篇 |
2020年 | 343篇 |
2019年 | 276篇 |
2018年 | 229篇 |
2017年 | 275篇 |
2016年 | 236篇 |
2015年 | 266篇 |
2014年 | 590篇 |
2013年 | 645篇 |
2012年 | 535篇 |
2011年 | 552篇 |
2010年 | 461篇 |
2009年 | 418篇 |
2008年 | 453篇 |
2007年 | 428篇 |
2006年 | 373篇 |
2005年 | 315篇 |
2004年 | 273篇 |
2003年 | 194篇 |
2002年 | 162篇 |
2001年 | 146篇 |
2000年 | 135篇 |
1999年 | 95篇 |
1998年 | 83篇 |
1997年 | 81篇 |
1996年 | 70篇 |
1995年 | 69篇 |
1994年 | 66篇 |
1993年 | 80篇 |
1992年 | 51篇 |
1991年 | 54篇 |
1990年 | 41篇 |
1989年 | 25篇 |
1988年 | 28篇 |
1987年 | 25篇 |
1986年 | 23篇 |
1985年 | 37篇 |
1984年 | 30篇 |
1983年 | 29篇 |
1982年 | 27篇 |
1981年 | 21篇 |
1980年 | 19篇 |
1979年 | 25篇 |
1978年 | 16篇 |
1977年 | 16篇 |
1976年 | 22篇 |
1975年 | 16篇 |
1974年 | 12篇 |
排序方式: 共有9033条查询结果,搜索用时 46 毫秒
1.
2.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献
3.
4.
随着人类基因组测序、生物大数据信息分析、分子病理检测和人工智能辅助病理诊断等技术进步及其应用, 临床医学发展迈向精准诊疗时代。这一时代背景下, 传统诊断病理学迎来前所未有的历史机遇, 正在向"下一代诊断病理学(next-generation diagnostic pathology)"迈进。下一代诊断病理学以病理形态和临床信息为诊断基础, 以分子检测与生物信息分析、智慧制样与流程质控、智能诊断与远程会诊、病灶活体可视化与"无创"病理诊断等创新前沿交叉技术为主要特征, 以多组学和跨尺度整合诊断为病理报告内容, 实现对疾病的"最后诊断", 并预测疾病演进和结局、建议治疗方案和评估治疗反应, 形成新的疾病诊断"金标准"。未来, 需要激发病理学科创新活力, 加快下一代诊断病理学成熟和应用, 重塑病理学科理论和技术体系, 发挥诊断病理学在疾病"防、诊、治、养"等过程中的重要作用, 促进临床医学进一步发展, 服务健康中国战略。 相似文献
5.
内生菌由细菌、真菌、古菌和原生生物组成,它们生活在植物的活体组织中,具有丰富的次级代谢产物多样性。人参内生菌在人参的生长发育、次级代谢产物的生成和环境适应等方面均有重要的促进作用,对人参的产量和品质有较大影响。随着人们在微生物领域研究的深入,高通量测序技术已经成为研究植物内生菌的重要方法。文章主要从人参内生菌分离与鉴定研究方法、人参内生菌的多样性、人参内生菌及其次级代谢产物的活性、人参内生菌对宿主的影响等4个方面对人参内生菌近年来的研究进展进行讨论,并对其发展方向提出展望,以期为药用植物内生菌研究和品质改良提供新思路、新方法。 相似文献
6.
7.
《European journal of surgical oncology》2021,47(8):1862-1874
BackgroundLocally advanced rectal cancer is routinely treated with neo-adjuvant long course chemoradiotherapy or short course radiotherapy, followed by total mesorectal excision. Not all patients respond to this treatment and there has been an emergence of novel treatment strategies designed to improve outcomes for these patients. This systematic review aims to assess the current novel neo-adjuvant treatment strategies being utilised in the treatment of patients with rectal cancer and how these impact pathological complete response (pCR) rates.MethodsA systematic review of the literature was performed to evaluate pathological response in patients with rectal cancer receiving novel neo-adjuvant therapy. EMBASE and Medline electronic databases were searched for relevant articles. Articles published between January 2008 and February 2019 were retrieved. Included studies underwent critical appraisal and complete pathological response rates were recorded.ResultsOf the initial 1074 articles identified, 217 articles fulfilled the inclusion criteria, of these 60 articles (4359 patients) were included. Neo-adjuvant therapy delivered included novel long course chemoradiation therapy, neoadjuvant chemotherapy alone, addition of a biological agent, total neo-adjuvant therapy, novel short course radiation therapy and studies utilising biomarkers to select patients for therapy. Complete pathological response rates ranged from 0 to 60%.ConclusionA validated novel neo-adjuvant therapy that significantly increases pCR rates in patients with rectal cancer has not been identified. 相似文献
8.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2022,34(2):e97-e103
Modern artificial intelligence techniques have solved some previously intractable problems and produced impressive results in selected medical domains. One of their drawbacks is that they often need very large amounts of data. Pre-existing datasets in the form of national cancer registries, image/genetic depositories and clinical datasets already exist and have been used for research. In theory, the combination of healthcare Big Data with modern, data-hungry artificial intelligence techniques should offer significant opportunities for artificial intelligence development, but this has not yet happened. Here we discuss some of the structural reasons for this, barriers preventing artificial intelligence from making full use of existing datasets, and make suggestions as to enable progress. To do this, we use the framework of the 6Vs of Big Data and the FAIR criteria for data sharing and availability (Findability, Accessibility, Interoperability, and Reuse). We share our experience in navigating these barriers through The Brain Tumour Data Accelerator, a Brain Tumour Charity-supported initiative to integrate fragmented patient data into an enriched dataset. We conclude with some comments as to the limits of such approaches. 相似文献
9.
Marc Evans MD Susanne Engberg MD Mads Faurby MSc João Diogo Da Rocha Fernandes MSc Pollyanna Hudson MSc William Polonsky PhD 《Diabetes, obesity & metabolism》2022,24(3):377-390
We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world noninterventional studies (published between 2010 and October 2020) reporting estimates of adherence to and persistence with antidiabetic medication in adults with T2D, and associations with glycaemic control, microvascular and/or macrovascular complications, hospitalizations and healthcare costs. Ninety-two relevant studies were identified, the majority of which were retrospective and reported US data. The proportions of patients considered adherent (median [range] 51.2% [9.4%-84.3%]) or persistent (median [range] 47.7% [16.9%-94.0%]) varied widely across studies. Multiple studies reported an association between greater adherence/persistence and greater reductions in glycated haemoglobin levels. Better adherence/persistence was associated with fewer microvascular and/or macrovascular outcomes, although there was little consistency across studies in terms of which outcomes were improved. More adherent and more persistent patients were typically less likely to be hospitalized or to have emergency department visits/admissions and spent fewer days in hospital annually than less adherent/persistent patients. Greater adherence and persistence were generally associated with lower hospitalization costs, higher pharmacy costs and lower or budget-neutral total healthcare costs compared with lower adherence/persistence. In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget-neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes. 相似文献
10.